MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Type of Mesothelioma:

Loaction of the turmors and cell characteristics are among the differientiating factors in mesothelioma.

Targeting Calcium Signalling in Malignant Mesothelioma.

Cancers 2019 November 21 [Link] Martinotti S, Patrone M, Moccia F, Ranzato E Abstract Calcium ions (Ca2+) are central in cancer development and growth, serving as a major signaling system determining the cell’s fate. Therefore, the investigation of the functional roles of ion channels in cancer development may identify novel approaches for determining tumor prognosis. […]

Comments Off on Targeting Calcium Signalling in Malignant Mesothelioma.

A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.

PloS One 2019 November 25 [Link] Minchom A, Mak D, Gunapala R, Walder D, Kumar R, Yousaf N, Hodgkiss A, Bhosle J, Popat S, O’Brien MER Abstract OBJECTIVES: Vitamin supplementation reduces pemetrexed toxicity. Raised plasma homocysteine reflects deficiency in vitamin B12 and folate, and is suppressed by supplementation. This observational study of 112 patients receiving […]

Comments Off on A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.

Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.

International Journal of Molecular Science 2019 November 19 [Link] Belfiore A, Busico A, Bozzi F, Brich S, Dallera E, Conca E, Capone I, Gloghini A, Volpi CC, Cabras AD, Pilotti S, Baratti D, Guaglio M, Deraco M, Kusamura S, Perrone F Abstract Background-There are currently no effective therapies for diffuse malignant peritoneal mesothelioma (DMPM) patients […]

Comments Off on Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.

Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.

Journal of Cellular and Molecular Medicine 2019 November 21 [Link] Miao J, Kyoyama H, Liu L, Chan G, Wang Y, Urisman A, Yang YL, Liu S, Xu Z, Bin H, Li H, Jablons DM, You L Abstract Cyclin-dependent kinase 7 (CDK7) is a protein kinase that plays a major role in transcription initiation. Yes-associated protein […]

Comments Off on Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.

Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.

Journal of Toxicology and Environmental Health 2019 November 22 [Link] Celsi F, Crovella S, Moura RR, Schneider M, Vita F, Finotto L, Zabucchi G, Zacchi P, Borelli V Abstract Two of the major cancerous diseases associated with asbestos exposure are malignant pleural mesothelioma (MPM) and lung cancer (LC). In addition to asbestos exposure, genetic factors […]

Comments Off on Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.

Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.

Oncotarget 2019 November 5 [Link] Donnenberg AD, Luketich JD, Donnenberg VS Abstract INTRODUCTION: We compared the secretome of metastatic (non-small cell lung cancer (NSCLC)) and primary (mesothelioma) malignant pleural effusions, benign effusions and the published plasma profile of patients receiving chimeric antigen receptor T cells (CAR-T), to determine factors unique to neoplasia in pleural effusion […]

Comments Off on Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.

Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.

Clinical Lung Cancer 2019 October 25 [Link] Paajanen J, Ilonen I, Lauri H, Järvinen T, Sutinen E, Ollila H, Rouvinen E, Lemström K, Räsänen J, Ritvos O, Koli K, Myllärniemi M Abstract BACKGROUND: Previous preclinical studies have shown that activin A is overexpressed in malignant pleural mesothelioma (MPM), associates with cancer cachexia, and is observed […]

Comments Off on Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.

The YAP1 signaling inhibitors, verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype.

Molecular Cancer Research 2019 Novemver 15 [Link] Eckert RL, Kandasamy S, Adhikary G, Rorke EA, Friedberg JS, Mickle MB, Alexander HR Abstract Mesothelioma is an aggressive cancer that has a poor prognosis. Tumors develop in the mesothelial lining of the pleural and peritoneal cavities in response to asbestos exposure. Surgical debulking followed by chemotherapy is […]

Comments Off on The YAP1 signaling inhibitors, verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype.

[Screening of occupational exposure to asbestos and silica by job-exposure matrix among patients with lung cancer and mesothelioma].

Revue des Maladies Respiratoires 2019 November 11 [Link] Lorentz E, Despreaux T, Quignette A, Chinet T, Descatha A Abstract INTRODUCTION: In the context of underreporting of occupational diseases, the aim was to study the validity of silica and asbestos job-exposure matrices in screening occupational exposure in the field of thoracic oncology. METHODS: Fifty patients hospitalized […]

Comments Off on [Screening of occupational exposure to asbestos and silica by job-exposure matrix among patients with lung cancer and mesothelioma].

Intraperitoneal delivery of chemotherapeutic agents for the treatment of peritoneal metastases: Current challenges and how to overcome them.

Expert Opinion on Drug Delivery 2019 November 14 [Link] Sugarbaker PH Abstract Introduction: Peritoneal metastases of cancer remains a major cause of an adverse outcome and death following surgical treatment of malignancies that occur within the abdomen and pelvis. The administration of a chemotherapy solution directly into the peritoneal space has been used to improve […]

Comments Off on Intraperitoneal delivery of chemotherapeutic agents for the treatment of peritoneal metastases: Current challenges and how to overcome them.